Investigator Studies Program (MISP): Heart Failure
Effective February 2021, the Heart Failure Investigator Studies Program (MISP) Committee will accept proposals within our current areas of interest (AOI) on a rolling basis. Reviews will occur monthly. This is a competitive process that will be conducted by the Heart Failure MISP. Decisions will be made on the basis of scientific merit and strategic fit within the AOIs. The program requests that investigators specify how they will support diversity in enrollment to include traditionally underrepresented minorities/ethnic groups.
The following areas are of interest to the Investigator Studies Program Committee:
- Investigate sGC stimulation vs. RAAS.
- Investigate sGC stimulation without and under full RAAS inhibition.
- Investigate the MOA of vericiguat in the presence or absence of Entresto / SGLT2i
- Investigate secondary benefits of sGC modulation.
- Investigate potential vericiguat benefits for novel quality of life metrics (e.g. digital biomarkers, sleep quality, activity tracking, pharmacoeconomic/lab draws, etc.)
- Investigate programs to support patients in the adherence to vericiguat (e.g. tele-health, structural / systematic, etc)
- Investigate additional clinical benefits of vericiguat in HF patients who are using vericiguat consistent with the approved label
- Investigate potential benefits related to novel plasma / imaging / urinary biomarkers and devices (e.g. novel peptides, strain analysis, hemodynamic monitoring, etc)
- Cardio-Oncology (e.g. prophylaxis, post-treatment)
Please complete a protocol and detailed budget via Visiontracker
, the Company's on-line study management system (in US). The proposals will be collectively reviewed and selected by the Heart Failure MISP Committee.
This site is intended for US investigators only. Investigators outside of the US interested in submitting research proposals to the Investigator
Studies Program should contact their local MSD office